Latest research on Soliris

Soliris is a formulation of eculizumab which is a recombinant humanized monoclonal IgG2/4;κ antibody produced by murine myeloma cell culture and purified by standard bioprocess technology. Eculizumab contains human constant regions from human IgG2 sequences and human IgG4 sequences and murine complementarity-determining regions grafted onto the human framework light- and heavy-chain variable regions. Eculizumab is composed of two 448 amino acid heavy chains and two 214 amino acid light chains and has a molecular weight of approximately 148 kDa.

Latest findings

Eculizumab which is formulated to Soliris is a humanized monoclonal antibody against complement protein C5 that inhibits terminal complement activation [5]. [source, 2016]
To this end we used eculizumab (Soliris), a humanized antibody against C5 [25], that binds to an epitope within the MG7 domain [26] and would cause steric hindrance of C5 binding to C3b in the proposed model (Fig. 5b). [source, 2015]
Her clinical presentation was thought to be consistent with a microangiopathic hemolytic anemia so she underwent hemodialysis and was treated with Soliris and Prednisone 1 mg/kg for atypical HUS. [source, 2015]
She completed 4 weekly Rituxan doses and received weekly Soliris for 3 weeks, and her factor V levels normalized to 54% activity with undetectable inhibitor titers. [source, 2015]
Eculizumab (Soliris, Alexion Pharmaceuticals, Cheshire, CT, USA) is an inhibitor of C5 that prevents the formation of the membrane attack complexes at the bottom of the complement cascade. [source, 2015]
An orphan medicinal product, eculizumab (Soliris, Alexion Pharmaceuticals) is a recombinant, fully humanized hybrid IgG2/IgG4 monoclonal antibody directed against human complement component C5; inhibition of complement activation at the level of C5 creates a functional C5 deficiency [4]. [source, 2014]
In prescribing information provided by the US Food and Drug Administration, the boxed warnings recommend that clinicians “comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies,” and “immunize patients with a meningococcal vaccine at least 2 weeks prior to administering the first dose of Soliris, unless the risks of delaying Soliris therapy outweigh the risks of developing a meningococcal infection [5]. [source, 2014]
Similarly, in the summary of product characteristics from the European Medicines Agency, patients who are not currently vaccinated against Neisseria meningitides are contraindicated to receive eculizumab therapy; the Agency provides clear statements that “to reduce the risk of infection, all patients must be vaccinated at least 2 weeks prior to receiving Soliris. [source, 2014]
PNH patients must be vaccinated 2 weeks prior to Soliris initiation. aHUS patients who are treated with Soliris less than 2 weeks after receiving a meningococcal vaccine must receive treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination. [source, 2014]
She was vaccinated against meningococcal infection and initiated on eculizumab (Soliris, Alexion Pharmaceuticals) with prophylactic antibiotics for the first 14 days. [source, 2014]